Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 2Radiation Injuries 1Peripheral Nervous System Diseases 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Gangliosidosis, GM1 1Gangliosidoses 1Colorectal Neoplasms 1Cognitive Dysfunction 1Brain Neoplasms 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × G(M1) Ganglioside × Clear all
NCT02093910 2014-11-19

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Sun Yat-sen University

Phase 2 Unknown
100 enrolled
Plasma cell

Multiple Myeloma, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡